Trial Profile
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms BIBC
- 06 Aug 2012 New trial record